Trailing Dividend / Share
$0.00
Avidity Biosciences, Inc. (RNA) Dividend History
Income profile from 2018 to 2025 with payout safety and yield-on-cost trend
Dividend Yield
N/A
Payout Ratio
N/A
Unknown
Dividend Streak
1 years
3-Second Income Check
Safety
Payout ratio data not available yet.
Consistency
1 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
Dividend Scorecard
Yield & Income
Dividend YieldN/A
Trailing DPS$0.00
FrequencyN/A
Payments / 12M0
Payout Safety
Earnings PayoutN/A
Earnings SafetyUnknown
FCF PayoutN/A
FCF SafetyUnknown
Piotroski F-Score2/9
Growth
Growth Streak1 years
3Y CAGRN/A
5Y CAGRN/A
Yield on Cost (5Y)N/A
YOC Trendunknown
Total Returns
Buyback Yield0.0%
Total Shareholder Yield0.0%
1Y Total Return-51.9%
5Y Total Return-43.0%
Estimated $10K growth (return + dividends):
5Y ago$5,70410Y ago$5,17520Y ago$5,175
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). RNA's recent 5Y regime has been stronger than its full 10Y period, so 5Y can appear higher than 10Y.
Dividend History
No dividend payment history available
This company has not paid dividends during the available data period.
Dividend Analysis
Payout Safety
Avidity Biosciences, Inc. has limited earnings payout data (Unknown).
Piotroski F-Score: 2/9 — weak financial health.
Growth Track Record
RNA has raised its dividend for 1 consecutive year.
Total Shareholder Returns
Beyond cash dividends, RNA returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -43.0%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $5,175 today.
Annual Dividend History
8 years of dividend data
GrowthDecline
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | — | 0 | $-4.97 | — | — | — |
| 2024 | $0.00 | — | 0 | $-2.89 | — | — | — |
| 2023 | $0.00 | — | 0 | $-2.91 | — | — | — |
| 2022 | $0.00 | — | 0 | $-3.34 | — | — | — |
| 2021 | $0.00 | — | 0 | $-2.85 | — | — | — |
| 2020 | $0.00 | — | 0 | $-2.05 | — | — | — |
| 2019 | $0.00 | — | 0 | $-0.86 | — | — | — |
| 2018 | $0.00 | — | 0 | $-0.58 | — | — | — |
See RNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RNA vs AGIO
See how RNA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
How much dividend does RNA pay per share?
Avidity Biosciences, Inc. (RNA) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.
When is RNA's next ex-dividend date?
RNA's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. RNA typically pays dividends quarterly.
Is RNA's dividend safe?
RNA's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The 1-year growth streak provides moderate confidence.
How many years has RNA increased its dividend?
RNA has 1 consecutive years of dividend growth. The 5-year dividend CAGR is N/A.
How often does RNA pay dividends?
Avidity Biosciences, Inc. pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 7+ years from 2018 to 2025.
How much would $10,000 invested in RNA grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in RNA five years ago would be worth approximately $5,704 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is RNA's yield on cost for long-term holders?
RNA's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.